| Name | Title | Contact Details |
|---|---|---|
Shelly Selvaraj |
Senior Vice President of Information Technology | Profile |
Jacob Leach |
Chief Technology Officer | Profile |
Jacob Leach |
Executive Vice President, Chief Technology Officer and Chief Operating Officer | Profile |
John Iraci |
Director, IT Infrastructure and Operations | Profile |
Atenda Health Care Solutions is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn`t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world`s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.
I.V. League Medical is a Oxnard, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adagio Medical, Inc. is a privately held company located in Laguna Hills, California developing innovative cryoablation technologies that create continuous, linear, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter and ventricular tachycardia.
Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Our primary focus is helping physicians conquer even the most difficult disease states, including arterial calcium, given the complications it presents for the millions who suffer from peripheral arterial disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes.